HTG Molecular Diagnostics, Inc.
HTG Molecular Diagnostics, Inc.
Your view on HTGMQ
Overview
What the company does, where it operates, and who runs it.
About HTG Molecular Diagnostics, Inc.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- John L. Lubniewski
- Headquarters
- 3430 East Global Loop, Tucson, AZ, US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- John L. Lubniewski
- Headquarters
- 3430 East Global Loop, Tucson, AZ, US
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets.
Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel.
The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories.
The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
On June 5, 2023, HTG Molecular Diagnostics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for HTG Molecular Diagnostics, Inc., and the rating behind it. HTGMQ last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for HTG Molecular Diagnostics, Inc.. Starting points for HTG Molecular Diagnostics, Inc.: EPS -$24.28, beta 2.76 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for HTG Molecular Diagnostics, Inc.. HTG Molecular Diagnostics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for HTG Molecular Diagnostics, Inc.. Trailing twelve-month EPS for HTG Molecular Diagnostics, Inc. stands at -$24.28. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for HTG Molecular Diagnostics, Inc.. HTG Molecular Diagnostics, Inc. has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
HTG Molecular Diagnostics, Inc. valued side by side against its closest peers. HTG Molecular Diagnostics, Inc. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold HTG Molecular Diagnostics, Inc., and how their positions are changing. At a $221 market value, institutional positions materially move HTG Molecular Diagnostics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by HTG Molecular Diagnostics, Inc. executives and directors. Shares of HTG Molecular Diagnostics, Inc. have traded between $0.0001 and $0.0010 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming HTG Molecular Diagnostics, Inc.. HTG Molecular Diagnostics, Inc. is a $221 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming HTG Molecular Diagnostics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for HTG Molecular Diagnostics, Inc.. Coverage tracks HTG Molecular Diagnostics, Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.